ENSC — Ensysce Biosciences Share News
0.000.00%
Last trade - 00:00- $9.15m
- $8.35m
- $5.07m
Brief: Ensysce Biosciences Says Received Notice From Nasdaq Stating Co Was Not In Compliance With Nasdaq Listing Rule 5550(A)(2)
Ensysce Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Ensysce Biosciences Inc expected to post a loss of 93 cents a share - Earnings Preview
Ensysce Biosciences Inc expected to post a loss of 93 cents a share - Earnings Preview
Brief: Ensysce Biosciences Announces Successful Meeting with FDA For PF614-MPAR, A Next Generation Opioid With Overdose Protection
Ensysce Biosciences climbs on 'breakthrough therapy' tag for its opioid pain killer
Ensysce Biosciences rises on 'breakthrough therapy' tag for its pain relief drug
Ensysce Biosciences Inc expected to post a loss of $1.06 a share - Earnings Preview
Ensysce Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Ensysce Biosciences Inc expected to post a loss of $2.73 a share - Earnings Preview
Ensysce Biosciences regains compliance with Nasdaq listing rule, shares rise
Brief: Ensysce Biosciences On June 13 Regained Compliance With Equity Requirement In Nasdaq Listing Rule
Brief: Ensysce Biosciences Says On March 28, Filed Amendment to Certificate Of Incorporation To Effect 1-For-12 Reverse Stock Split Of Common Stock
Brief: Ensysce Biosciences - On January 27, Co Received Notice In Form Of Deficiency Letter From Nasdaq - Filing
Brief: Ensysce Biosciences Inc Says On Dec 14, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Apple, Activision Blizzard, Manchester United
Brief: Ensysce Biosciences- On Oct 27 Filed Amendment To Third Amended, Restated Certificate Of Incorporation To Effect 1-For-20 Reverse Stock Split Of Common Stock
Brief: Ensysce Biosciences Inc Files For Offering Of $12.5 Million Of Common Stock And Warrants To Purchase Shares Of Common Stock
Ensysce Biosciences up on partnership for pain therapy development